Selda ÇELİK, Cemile İDİZ, Elif BAĞDEMİR, Sevim PURİSA, Nevin DİNÇÇAĞ, İLHAN SATMAN

Diyabetlilerde Kendi Kendine Kan Şekeri İzlemi ile HbA1c ve Diyabet Komplikasyonlarının Karşılaştırılması

Amaç: Bu çalışma diabetes mellitus nedeniyle izlenen hastalarda kan şekeri ölçüm sıklığı ile diyabet regülasyonu ve diyabetin komplikasyonları arasındaki ilişkiyi belirlemek amacıyla yapılmıştır. Bireyler ve Yöntem: Çalışma 951 diyabetli hastanın (tip1= 90, tip2= 861) dosyalarının retrospektif olarak incelenmesi ile gerçekleştirilmiştir. Hastaların yaşı, cinsiyeti, boyu, ağırlığı, diyabet tipi, diyabet süresi, diyabet tedavisi, hemoglobin A1c (HbA1c) değeri, nöropati varlığı, nefropati varlığı, diyabetik ayak varlığı, hipertansiyon varlığı, kan şekeri ölçüm sıklığı bilgileri not edilmiştir. Kan şekeri ölçüm sıklıklarına göre hastalar 3 gruba ayrılmıştır: haftada en az iki gün toplam 8 kez kan şekeri ölçümü yapanlar (grup 1), haftada iki günden az ve 8 ölçümden az kan şekeri ölçümü yapanlar (grup 2), düzensiz kan şekeri ölçümü yapmalarına rağmen doktor kontrolüne gelmeden önceki 2 gün içerisinde 8 kez kan şekeri ölçümü yapanlar (grup 3). Bulgular: Hastaların 548’i kadın, 403’ü erkek, ortalama yaş 58.12±13.17 yıldır. Gruplar arasında HbA1c (p

Comparison of Self-Monitoring Blood Glucose with HbA1c and Diabetes Complications in Diabetics

Aim: This study aimed to determine the relationship between the frequency of measuring blood glucose levels and the complications and regulation of diabetes in patients under follow-up due to diabetes mellitus. Subjects and Method: This study was conducted via retrospective evaluation of patient files of 951 diabetics (90 with type 1 diabetes and 861 with type 2 diabetes). Patient information including age, gender, height, weight, type of diabetes, duration of diabetes, treatment of diabetes, hemoglobin A1c (HbA1c) value, presence of neuropathy, presence of nephropathy, presence of diabetic foot, presence of hypertension, and frequency of measuring blood glucose levels were recorded. Patients were divided into 3 groups by the frequency of measuring blood glucose levels, where those who measured blood glucose levels a total of 8 times for at least two days a week were assigned to group 1, those who measured blood glucose levels less than 8 times for less than two days a week were assigned to group 2, and those who measured blood glucose levels 8 times in the 2 days prior to the control visit, who had previously measured blood glucose levels in an irregular manner were assigned to group 3. Results: Of the patients, 548 were females and 403 were males, with a mean age of 58.12±13.17 years. There was a significant difference in the parameters of HbA1c (p

PDF

___

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2017;40(1):1-135.
Bennet PH, Knowler WC. Definition, Diagnosis and Classification of Diabetes Mellitus and Glucose Homeostaisis. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, editors. Joslin Diabetes Mellitus. 14th ed. Lippincott Williams &Wilkins; 2005.p.331-39.
Türkiye Endokrinoloji ve Metabolizma Derneği (TEMD) Diabetes Mellitus Çalışma ve Eğitim Grupları. Diabetes Mellitus ve Komplikasyonlarının Tanı Tedavi ve İzlem Kılavuzu. İstanbul, Türkiye Endokrinoloji ve Metabolizma Derneği. 2017, Ankara.
Dinççağ N. Tip 1 Diyabetin Epidemiyolojisi. Diyabet El Kitabı. İstanbul Tıp Kitabevi; 2013. s. 35-43.
International Diabetes Federation. Diabetes Atlas. 8th ed. 2017. Available at: http://diabetesatlas.org/ resources/2017-atlas.html.
Yılmaz T. Tip 1 diabetes mellitus. İmamoğlu Ş, Ersoy C, editörler. Diabetes Mellitus. 3. baskı. Deomed Medikal Yayıncılık; İstanbul, 2009. s. 38-51.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2013;36(1):11-66.
Örük G, Çömlekçi A. Diabetes Mellitus Tedavisinde Genel Yaklaşım. Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, editörler. Yumuk V, çeviri editörü. Joslin’s Diabetes Mellitus. 1. baskı. İstanbul Medikal Yayıncılık, İstanbul; 2008. s.587-596.
Kabalak T, Çetinkalp Ş. Tip 2 diabetes mellitus. İmamoğlu Ş, Ersoy C, editörler. Diabetes Mellitus. 3. baskı. Deomed Medickal Yayıncılık, İstanbul; 2009. s. 54-72.
Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes. Eur J Epidemiol 2013;28:169–80.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137–49.
American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 2016;39(1):52-59.
Helgeson VS, Honcharuk E, Becker D, Escobar O, Siminerio L. A focus on blood glucose monitoring: relation to glycemic control and determinants of frequency. Pediatr Diabetes 2011;12(1):25-30.
American Diabetes Association. Glycemic Targets. Diabetes Care 2016;39(l):39-46.
Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, et al. EADSG Guidelines: Insulin Therapy in Diabetes. Diabetes Ther 2018;9(2):449-492.
McCall AL, Mullin CJ. Home monitoring of diabetes mellitus--a quiet revolution. Clin Lab Med 1986;6(2):215- 239.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-986.
Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin- dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991;230:101–108.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–2012.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23 (2):21-29.
American Diabetes Association. Cardiovascular Disease and Risk Management. Diabetes Care 2016;39(1):60-71.
American Diabetes Association. Microvascular Complications and Foot Care. Diabetes Care 2016;39(1):72-80.
Durán A, Martín P, Runkle I, Pérez N, Abad R, Fernández M, et al. Benefits of self-monitoring blood glucose in the management of new-onset type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic based interventional study with parallel groups. J Diabetes 2010;2:203-211.
Schnell O, Alawi H, Battelino T, Ceriello A, Diem P, Felton AM, et al. Self-monitoring of blood glucose in type 2 diabetes: recent studies. J Diabetes Sci Technol 2013;7:478-488.
Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. Structured self monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011;34:262-267.
Klonoff DC, Blonde L, Cembrowski G, Chacra AR, Charpentier G, Colagiuri S, et al. Consensus report: the current role of self-monitoring of blood glucose in non- insulin-treated type 2 diabetes. J Diabetes Sci Technol 2011;5:1529-1548.
Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-3087.
American Diabetes Association. Introduction. Diabetes Care 2016;39 (1):1-2.
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653.
Ozgur R, Mavis O, Ayalp P. Tip 2 diabetes mellituslu hastalarda evde glukoz takibi sıklığı ve HbA1c ile ilişkisi. Okmeydanı Tıp Dergisi 2011;27(2):70-75.
Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, et al. T1D Exchange Clinic Network. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobinA1c levels in T1D exchange clinic registry participants. Diabetes Care 2013;36(7):2009-2014.
Murata GH, Shah JH, Hoffman RM, Wendel CS, Adam KD, Solvas PA, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care 2003;26(6):1759– 1763.
Kim KS. Self-monitoring of blood glucose in patients with insulin-treated type 2 diabetes mellitus. Diabetes Metab J 2018;42(1):26-27.
Sosyal Güvenlik Kurumu Sağlık Uygulama Tebliği. 18 Şubat 2015. Erişim: http://istanbultip.istanbul. edu.tr/wp-content/uploads/2015/02/18-02-2015- De%C4%9Fi%C5%9Fiklik-i%C5%9Flenmi%C5%9F- g%C3%BCncel-2013-SUT.pdf. Erişim tarihi: 3 Ocak 2017.
Elgart JF, González L, Prestes M4, Rucci E, Gagliardino JJ. Frequency of self-monitoring blood glucose and attainment of HbA1c target values. Acta Diabetol 2016;53(1):57-62.
Erbach M, Freckmann G, Hinzmann R, Kulzer B, Ziegler R, Heinemann L, et al. Interferences and limitations in blood glucose self-testing: An overview of the current knowledge. J Diabetes Sci Technol 2016;22(5):1161-1168.